JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development

The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.

Scroll to Top